Changes in the metabolites of cerebrospinal fluid induced by rTMS in treatment-resistant depression: A pilot study.

Depression / therapy Depressive Disorder, Treatment-Resistant / therapy Humans Kynurenine Pilot Projects Prefrontal Cortex / physiology Transcranial Magnetic Stimulation Treatment Outcome
Cerebrospinal fluid Repetitive transcranial magnetic stimulation Treatment-resistant depression

Journal

Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385

Informations de publication

Date de publication:
07 2022
Historique:
received: 19 11 2021
revised: 04 04 2022
accepted: 12 05 2022
pubmed: 21 5 2022
medline: 10 6 2022
entrez: 20 5 2022
Statut: ppublish

Résumé

Repetitive transcranial magnetic stimulation (rTMS) improves depressive symptoms in treatment-resistant depression (TRD). This study aimed to analyze changes in cerebrospinal fluid (CSF) metabolites in patients with TRD after rTMS. Five patients with TRD were enrolled in a high frequency (10-Hz) rTMS study. The concentration of 72 CSF metabolites were measured at baseline and at the end of the 6-week rTMS treatment. rTMS significantly increased CSF niacinamide, kynurenine, and creatinine levels and significantly decreased CSF cystine levels, but not the levels of the other 68 CSF metabolites. This is the first CSF metabolomics study on patients with TRD who underwent rTMS.

Identifiants

DOI: 10.1016/j.psychres.2022.114636 PMID: 35594657
pubmed: 35594657
pii: S0165-1781(22)00236-0
doi: 10.1016/j.psychres.2022.114636
pii:
doi:

Substances chimiques

Kynurenine 343-65-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114636

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Hiroshi Tateishi (H)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan. Electronic address: tateishh@cc.saga-u.ac.jp.

Daiki Setoyama (D)

Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Maidashi Higashi-ku 3-1-1, Fukuoka, 812-8582, Japan.

Takahiro A Kato (TA)

Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Maidashi Higashi-ku 3-1-1, Fukuoka, 812-8582, Japan. Electronic address: takahiro@npsych.med.kyushu-u.ac.jp.

Dongchon Kang (D)

Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Maidashi Higashi-ku 3-1-1, Fukuoka, 812-8582, Japan.

Jun Matsushima (J)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Kojiro Nogami (K)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Seiji Mawatari (S)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Ryohei Kojima (R)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Yuka Fujii (Y)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Yuta Sakemura (Y)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Takumi Shiraishi (T)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Yoshiomi Imamura (Y)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Toshihiko Maekawa (T)

Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Maidashi Higashi-ku 3-1-1, Fukuoka, 812-8582, Japan.

Toyoko Asami (T)

Department of Rehabilitation Medicine, Saga University Hospital, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Yoshito Mizoguchi (Y)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Akira Monji (A)

Department of Psychiatry, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, 849-8501, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Comportement et mécanismes comportementaux › Émotions › Dépression › Changes in the metabolites of cerebrospinal...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Trouble dépressif › Trouble dépressif résistant aux traitements › Changes in the metabolites of cerebrospinal...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Changes in the metabolites of cerebrospinal...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Cynurénine › Changes in the metabolites of cerebrospinal...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Projets pilotes › Changes in the metabolites of cerebrospinal...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Lobe frontal › Cortex préfrontal › Changes in the metabolites of cerebrospinal...
questionsmedicales.fr › Thérapeutique › Magnétothérapie › Stimulation magnétique transcrânienne › Changes in the metabolites of cerebrospinal...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Changes in the metabolites of cerebrospinal...